Filing Flows › Gilead Sciences (GILD) › How it makes money
How Gilead Sciences (GILD) makes money
Gilead Sciences (GILD) made $8.3B of revenue in the third quarter 2026 (Q3 2026), +14% from a year earlier. Total HIV brought in $6.3B (75%); Trodelvy brought in $506M (6%); Total Cell Therapy brought in $355M (4%). Of every dollar of revenue, 42¢ was left as operating profit, 29¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Total HIV | $6.3B | 75.3% | — | +20% |
| ↳ Biktarvy | $4.1B | 48.8% | — | +10% |
| ↳ Descovy | $1.0B | 12.6% | — | +49% |
| ↳ Total Oncology | $860M | 10.3% | — | +9% |
| ↳ Yeztugo | $305M | 3.7% | — | +682% |
| Trodelvy | $506M | 6.1% | — | +42% |
| Total Cell Therapy | $355M | 4.3% | — | -18% |
| Genvoya | $339M | 4.1% | — | -10% |
| Yescarta | $294M | 3.5% | — | -16% |
| Odefsey | $286M | 3.4% | — | +3% |
| Sofosbuvir/Velpatasvir | $274M | 3.3% | — | -11% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $8.3B | 100.0% |
| Operating profit | $3.5B | 41.6% |
| Income tax | $634M | 7.6% |
| Net earnings | $2.4B | 29.2% |
| Operating cash flow | $5.0B | 60.5% |
| Free cash flow | $4.8B | 57.6% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $8.3B | +7% |
| Q2 2026 | $7.8B | +10% |
| Q1 2026 | $7.0B | +4% |
| Q4 2025 | $7.9B | +5% |
| Q3 2025 | $7.8B | +3% |
| Q2 2025 | $7.1B | +2% |
| Q1 2025 | $6.7B | -0.3% |
From Gilead Sciences' 10-Q filed Oct 30, 2026 (on EDGAR).
Questions
How does Gilead Sciences make money?
Gilead Sciences (GILD) made $8.3B of revenue in the third quarter 2026 (Q3 2026), +14% from a year earlier. Total HIV brought in $6.3B (75%); Trodelvy brought in $506M (6%); Total Cell Therapy brought in $355M (4%). Of every dollar of revenue, 42¢ was left as operating profit, 29¢ was left as net earnings.
What is Gilead Sciences' biggest business?
Total HIV: $6.3B in the third quarter 2026, 75% of revenue, +20% from a year earlier.
What is Gilead Sciences' profit margin?
Net earnings were $2.4B, 29.2% of revenue, in the third quarter 2026; the operating margin was 41.6%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.